Last reviewed · How we verify

NCT06629402: CPT

Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)

Completed Phase 2 Last updated 8 October 2024
What this trial tests

Phase 2 trial testing PF614 in Acute Pain in 16 participants. Completed in 15 November 2023.

Timeline
5 October 2023
Primary endpoint
14 November 2023
15 November 2023

Quick facts

Lead sponsorEnsysce Biosciences
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment16
Start date5 October 2023
Primary completion14 November 2023
Estimated completion15 November 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ensysce Biosciences — full company profile →

Who can join

Adults 18 to 55, male only, with Acute Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the study is to evaluate the onset of analgesia following administration of a single oral dose of PF614 (50 mg or 100 mg) or placebo in healthy male subjects in an experimental pain model (cold pressor test \[CPT\]).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of PF614

Trials testing the same drug.

Other recruiting trials for Acute Pain

Currently open trials in the same condition.

Other Ensysce Biosciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06629402.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing